Takeda's $21.44 close tops the high it set on Nov. 5 by 0.89%, extending a steady climb in the large-cap drugmaker.
Moves: Nov 13, 2026 · Alpha Vantage daily close
8 more related stocks · 1 has no US listing
Headquartered in Nihonbashi-honcho 2-chome, Chuo Fiscal year ends March NYSE: TAK takeda.com
Takeda Pharmaceutical Company Limited is a global R&D-driven biopharmaceutical company. It researches, develops, manufactures and commercializes pharmaceutical products and also earns out-licensing and service income. It reports a single operating segment.
Its revenue is organized into six key business areas:
- **Gastroenterology:** ENTYVIO, GATTEX/REVESTIVE, TAKECAB/VOCINTI, EOHILIA.
- **Rare Diseases:** TAKHZYRO, ELAPRASE, ADVATE, LIVTENCITY, VONVENDI, ADZYNMA.
- **Plasma-Derived Therapies:** immunoglobulins such as HYQVIA, CUVITRU and GAMMAGARD LIQUID, plus albumin.
- **Oncology:** ADCETRIS, LEUPLIN/ENANTONE, NINLARO, ICLUSIG, FRUZAQLA, MIMRYLO.
- **Vaccines:** QDENGA, NUVAXOVID.
- **Neuroscience:** VYVANSE/ELVANSE, TRINTELLIX, ORZEYFUL.
R&D focuses on three core therapeutic areas: Gastrointestinal and Inflammation, Neuroscience (orexin biology), and Oncology. Key late-stage assets include zasocitinib, arcotatug tavatecan, elritercept, TAK-928 and fazirsiran.
The United States is the largest market, followed by Europe, Japan, Latin America and China. The company is executing a transformation program and is led by CEO Julie Kim. Updated
Takeda's $21.44 close tops the high it set on Nov. 5 by 0.89%, extending a steady climb in the large-cap drugmaker.
Moves: Nov 13, 2026 · Alpha Vantage daily close
8 more related stocks · 1 has no US listing
Intel opened down 29%, a one-day drop of a size this name almost never posts, while the top of the board belongs entirely to pharma, led by Regeneron. Four of the five biggest decliners fell by double digits.
Takeda's ADRs just set a fresh 52-week high at $20.43, the fourth record in a week for the drugmaker.
Takeda Pharmaceutical touched $19.45, a fresh 52-week high that clears the September 17 peak by 2.1%. The ADR and the OTC line are both at the top of their range.
VEA dominates international portfolios, but a smaller rival fund uses a completely different logic to pick foreign stocks, and over the past five years it has quietly beaten the giant on both…
Retail traders are piling into Novavax on cancer-vaccine speculation, but the move that actually changed the company's business model happened quietly last week and has nothing to do with oncology.
BioCryst just turned profitable, its HAE drug Orladeyo is minting cash, and a rival's blockbuster acquisition just put the whole rare-disease sector in play. So which pharma giant has the most to…
Friday's top analyst upgrades and downgrades included Adobe, Citigroup, FedEx, Foot Locker, Hewlett Packard Enterprise, Intel, Medical Properties Trust, Nike, Qualcomm, Skyworks Solutions, Takeda Pharmaceutical and Under Armour.
Tuesday's additional top analyst upgrades and downgrades included Apollo Global Management, Cinemark, ConocoPhillips, EOG Resources, Fastly, Southwestern Energy, Sunrun and Takeda Pharmaceutical.
One of Cathie Wood's Ark Invest funds sold nearly 850,000 shares of Takeda Pharmaceutical on December 7.
One of Cathie Wood's Ark Invest funds sold over 690,000 shares of Takeda Pharmaceutical on November 16.
In this massively overbought market, health care stocks could benefit from a shift toward more defensive sectors. These five offer strong balance sheets, attractive dividend yields and improved cost structures, and they…
These four big pharmaceutical stocks are rated Buy by top Wall Street firms and look like very good ideas for investors, especially now that the market is overbought and the slow seasonal…
One of Cathie Wood's Ark Invest funds sold over 350,000 shares of Takeda Pharmaceutical on June 16.
One of Cathie Wood's Ark Invest funds sold over 225,000 shares of Takeda Pharma on June 15.
Takeda Pharmaceutical Company Limited is a global R&D-driven biopharmaceutical company. It researches, develops, manufactures and commercializes pharmaceutical products and also earns out-licensing and service income.
24/7 Wall St.'s 12-month price target for TAK is $27.31, rated Buy. The Wall Street consensus target is $24.59. TAK price prediction →